Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
Quoin Pharmaceuticals (NASDAQ: QNRX) has released the second episode of its 'Living with Netherton' video series, featuring 79-year-old Norma Coles, one of the earliest patients evaluated for Netherton Syndrome. The episode is part of the company's NETHERTON NOW awareness campaign.
Norma's remarkable story spans nearly eight decades, having been initially examined by Dr. Edward Netherton at the Cleveland Clinic in the late 1940s. Despite experiencing symptoms like fragile skin, recurring rashes, and 'bamboo hair,' she wasn't officially diagnosed until her mid-50s.
The company's lead product candidate, QRX003, is currently undergoing four clinical trials for Netherton Syndrome treatment. Initial data shows promising results, including improvements in skin healing, reduction in inflammation and pruritus, and enhanced quality of life. Quoin aims to develop the first FDA-approved treatment for this rare genetic disorder, as currently no approved treatments exist.
Quoin Pharmaceuticals (NASDAQ: QNRX) ha rilasciato il secondo episodio della sua serie di video 'Living with Netherton', con protagonista Norma Coles, una paziente di 79 anni e tra le prime ad essere valutata per la Sindrome di Netherton. L'episodio fa parte della campagna di sensibilizzazione NETHERTON NOW dell'azienda.
La storia straordinaria di Norma si estende per quasi otto decenni, avendo ricevuto la sua prima valutazione dal Dr. Edward Netherton presso la Cleveland Clinic alla fine degli anni '40. Nonostante manifestasse sintomi come pelle fragile, eruzioni cutanee ricorrenti e 'capelli a bamboo', non è stata ufficialmente diagnosticata fino ai suoi 50 anni.
Il principale candidato prodotto dell'azienda, QRX003, è attualmente sottoposto a quattro studi clinici per il trattamento della Sindrome di Netherton. I dati iniziali mostrano risultati promettenti, tra cui miglioramenti nella guarigione della pelle, riduzione dell'infiammazione e del prurito, e un aumento della qualità della vita. Quoin mira a sviluppare il primo trattamento approvato dalla FDA per questo raro disturbo genetico, poiché attualmente non esistono trattamenti approvati.
Quoin Pharmaceuticals (NASDAQ: QNRX) ha lanzado el segundo episodio de su serie de videos 'Living with Netherton', que presenta a Norma Coles, una paciente de 79 años y una de las primeras evaluadas por el Síndrome de Netherton. El episodio es parte de la campaña de concienciación NETHERTON NOW de la compañía.
La notable historia de Norma abarca casi ocho décadas, habiendo sido examinada inicialmente por el Dr. Edward Netherton en la Cleveland Clinic a finales de los años 40. A pesar de experimentar síntomas como piel frágil, erupciones recurrentes y 'cabello de bambú', no fue diagnosticada oficialmente hasta sus 50 años.
El principal candidato a producto de la compañía, QRX003, está actualmente en cuatro ensayos clínicos para el tratamiento del Síndrome de Netherton. Los datos iniciales muestran resultados prometedores, incluyendo mejoras en la cicatrización de la piel, reducción de la inflamación y el prurito, y una mejor calidad de vida. Quoin tiene como objetivo desarrollar el primer tratamiento aprobado por la FDA para este raro trastorno genético, ya que actualmente no existen tratamientos aprobados.
Quoin Pharmaceuticals (NASDAQ: QNRX)는 'Living with Netherton' 비디오 시리즈의 두 번째 에피소드를 발표하였으며, 79세의 노르마 콜스가 주인공으로 등장합니다. 그녀는 네더튼 증후군에 대해 평가받은 최초의 환자 중 한 명입니다. 이 에피소드는 회사의 NETHERTON NOW 인식 캠페인의 일환입니다.
노르마의 놀라운 이야기는 거의 80년을 아우르며, 그녀는 1940년대 후반 클리블랜드 클리닉에서 에드워드 네더튼 박사에 의해 처음 평가받았습니다. 그녀는 연약한 피부, 재발하는 발진, '대나무 머리카락'과 같은 증상을 겪었지만, 50대 중반까지 공식 진단을 받지 못했습니다.
회사의 주요 제품 후보인 QRX003는 현재 네더튼 증후군 치료를 위한 네 가지 임상 시험을 진행 중입니다. 초기 데이터는 피부 치유 개선, 염증 및 가려움증 감소, 그리고 삶의 질 향상 등 유망한 결과를 보여줍니다. Quoin은 현재 승인된 치료법이 없는 이 드문 유전 질환에 대해 FDA 승인을 받은 최초의 치료법을 개발하는 것을 목표로 하고 있습니다.
Quoin Pharmaceuticals (NASDAQ: QNRX) a publié le deuxième épisode de sa série de vidéos 'Living with Netherton', mettant en vedette Norma Coles, une patiente de 79 ans et l'une des premières évaluées pour le syndrome de Netherton. L'épisode fait partie de la campagne de sensibilisation NETHERTON NOW de l'entreprise.
L'histoire remarquable de Norma s'étend sur près de huit décennies, ayant été initialement examinée par le Dr Edward Netherton à la Cleveland Clinic à la fin des années 1940. Malgré des symptômes tels que peau fragile, éruptions cutanées récurrentes et 'cheveux en bambou', elle n'a été officiellement diagnostiquée qu'à la cinquantaine.
Le principal candidat produit de l'entreprise, QRX003, est actuellement soumis à quatre essais cliniques pour le traitement du syndrome de Netherton. Les données initiales montrent des résultats prometteurs, notamment des améliorations dans la guérison de la peau, une réduction de l'inflammation et du prurit, ainsi qu'une amélioration de la qualité de vie. Quoin vise à développer le premier traitement approuvé par la FDA pour ce rare trouble génétique, car il n'existe actuellement aucun traitement approuvé.
Quoin Pharmaceuticals (NASDAQ: QNRX) hat die zweite Episode seiner Video-Serie 'Living with Netherton' veröffentlicht, in der die 79-jährige Norma Coles vorgestellt wird, eine der frühesten Patientinnen, die auf das Netherton-Syndrom untersucht wurde. Die Episode ist Teil der Awareness-Kampagne NETHERTON NOW des Unternehmens.
Normas bemerkenswerte Geschichte erstreckt sich über fast acht Jahrzehnte, nachdem sie in den späten 1940er Jahren erstmals von Dr. Edward Netherton in der Cleveland Clinic untersucht wurde. Trotz der Symptome wie empfindliche Haut, wiederkehrende Ausschläge und 'Bambushaare' erhielt sie erst in ihren 50ern eine offizielle Diagnose.
Der Hauptproduktkandidat des Unternehmens, QRX003, befindet sich derzeit in vier klinischen Studien zur Behandlung des Netherton-Syndroms. Erste Daten zeigen vielversprechende Ergebnisse, darunter Verbesserungen bei der Hautheilung, eine Verringerung von Entzündungen und Juckreiz sowie eine verbesserte Lebensqualität. Quoin hat das Ziel, die erste von der FDA genehmigte Behandlung für diese seltene genetische Erkrankung zu entwickeln, da derzeit keine genehmigten Behandlungen existieren.
- None.
- None.
Episode Highlights a Truly Remarkable Patient Story Spanning 79 Years
Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company’s NETHERTON NOW website
ASHBURN, Va., April 10, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announced the release of the second episode in its “Living with Netherton” video series, part of the company’s broader NETHERTON NOW awareness campaign. This installment features Norma Coles, a 79-year-old woman whose diagnosis with Netherton Syndrome came decades after she was first evaluated by the condition’s namesake, Dr. Edward Netherton.
“Norma’s story thoughtfully bridges the earliest history of Netherton Syndrome with today’s urgent need for awareness and treatment,” said Denise Carter, Co-Founder and Chief Operating Officer of Quoin Pharmaceuticals. “Her powerful story reflects the reality of so many others who continue to go undiagnosed and unsupported. ‘Living with Netherton’ highlights individuals who have gone unheard and unrecognized for far too long, bringing to light the urgent need for effective Netherton Syndrome treatment.”
Norma’s story reflects the persistent challenges faced by patients living with this rare genetic disorder, including years of misdiagnosis, lack of awareness and limited medical guidance. For decades, she endured fragile skin, recurring rashes and brittle hair described as “bamboo hair”—a key characteristic of the disease. It wasn’t until her mid-50s that Norma was finally diagnosed, revealing a long-forgotten connection to Dr. Netherton himself, who studied her as a child at the Cleveland Clinic in the late 1940s.
“I guess I got it all started,” Norma says in the video, “but I didn’t know about it until I was 58.”
Her powerful reflection sheds light on how far the medical community has come, and how far it still must go. Today, 75 years after her first visit to Dr. Netherton, there remains no FDA-approved treatment for Netherton Syndrome.
Through the NETHERTON NOW campaign, Quoin is committed to raising awareness, improving education, and building advocacy for individuals and families affected by Netherton Syndrome. The video series is a central part of that effort, sharing real patient experiences to foster understanding of a disease that is often overlooked or misunderstood.
“Norma’s story reminds us why our work is critically important,” said Dr. Michael Myers, Co-Founder and Chief Executive Officer of Quoin Pharmaceuticals. “At a time when there are still no FDA-approved treatments for Netherton Syndrome, her experience illustrates both the long road so many patients have traveled and the urgency of delivering a transformative treatment option. Our ongoing clinical trials of QRX003 have generated encouraging initial data, including meaningful improvements in skin healing, clear reductions in painful inflammation and pruritus while leading to a much enhanced quality of life. We remain deeply committed to completing the development of what we hope will become the first approved treatment for this devastating disease. Stories like Norma’s fuel our determination every step of the way.”
Quoin’s lead product candidate, QRX003, is currently being evaluated in four clinical trials for the treatment of Netherton Syndrome. The Company’s goal is to develop the first FDA-approved therapy for the condition and provide meaningful support to a community that has waited far too long for answers.
The full video featuring Norma Coles can be viewed here https://www.youtube.com/watch?v=FtuiXC_IdXE
About QRX003
QRX003 is a topical lotion formulated with a proprietary delivery technology that contains a broad-spectrum serine protease inhibitor, whose mechanism of action is intended to perform the function of a specific protein called LEKTI. The absence of LEKTI in Netherton patients leads to excessive skin shedding, resulting in a highly porous and compromised skin barrier. QRX003 is designed to promote a more normalized skin-shedding process and the formation of a stronger and more effective skin barrier. For more information about Quoin’s current clinical trials please visit: https://quoinpharma.com/pipeline/#trials
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
For more information about Netherton Syndrome, Quoin’s clinical programs, or to stay updated on the Netherton Now series, visit nethertonnow.com.
Cautionary Note Regarding Forward Looking Statements
The Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “aim,” “design,” “expect,” “hope,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: Quoin aims to raising awareness, improving education, and building advocacy for individuals and families affected by Netherton Syndrome; completing the development of what Quoin hopes will become the first approved treatment for Netherton Syndrome; the Company’s goal to develop the first FDA-approved therapy for Netherton Syndrome and provide meaningful support to a community that has waited far too long for answers; the potential efficacy of QRX003 as a treatment for Netherton Syndrome; and Quoin’s products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to deliver a safe and effective treatment for Netherton Syndrome; whether the Company’s studies are successful in generating data that is sufficiently robust and comprehensive to support an NDA filing for QRX003 as an approved treatment for Netherton Syndrome; and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
FAQ
What is the significance of Norma Coles' story in the QNRX Netherton NOW campaign?
What progress has QNRX's QRX003 shown in clinical trials for Netherton Syndrome?
How many clinical trials is QNRX currently conducting for Netherton Syndrome?
What are the main symptoms of Netherton Syndrome highlighted in QNRX's patient story?
When does QNRX expect to deliver the first FDA-approved treatment for Netherton Syndrome?
